サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1415606

スニチニブリンゴ酸の世界市場：純度別、適応症別市場 - 2024年～2030年の予測

Sunitinib Malate Market by Purity (>97%, >98%, >99%), Indication (Gastrointestinal Stromal Tumors (GISTs), Pancreatic Neuroendocrine Tumors, Renal Cell Carcinoma (RCC)) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.76円
スニチニブリンゴ酸の世界市場：純度別、適応症別市場 - 2024年～2030年の予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

スニチニブリンゴ酸の市場規模は、2023年に1億2,327万米ドルと推定され、2024年には1億3,472万米ドルとなり、CAGR 9.79%で、2030年までに2億3,713万米ドルに達すると予測されます。

スニチニブリンゴ酸の世界市場

スニチニブリンゴ酸 Market-IMG1

FPNVポジショニングマトリックス

FPNVポジショニングマトリックスはスニチニブリンゴ酸市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、スニチニブリンゴ酸市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このように詳細な情報を得ることで、ベンダーはより多くの情報に基づいた意思決定を行い、市場での競争力を高めるための効果的な戦略を考案することができます。

主要企業プロファイル

本レポートでは、スニチニブリンゴ酸市場における最近の重要な動向を掘り下げ、主要ベンダーとその革新的なプロファイルを紹介しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 膵神経内分泌腫瘍（pNET）の有病率の上昇
      • 進行性pNETの治療に利用できる薬剤の選択肢は限られている
    • 抑制要因
      • スニチニブリンゴ酸医薬品の製造に必要な原材料のコストが高い
    • 機会
      • スニチニブリンゴ酸の新しい適応症と組み合わせを探るため、製薬会社による継続的な研究開発
      • がん治療における標的療法の利点について、患者とヘルスケア提供者の間で認識が高まる
    • 課題
      • 臨床試験中に報告された有害な心血管イベント
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 スニチニブリンゴ酸市場：純度別

  • >97%
  • >98%
  • >99%

第7章 スニチニブリンゴ酸市場：適応症別

  • 消化管間質腫瘍（GIST）
  • 膵神経内分泌腫瘍
  • 腎細胞がん（RCC）

第8章 南北アメリカのスニチニブリンゴ酸市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のスニチニブリンゴ酸市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカのスニチニブリンゴ酸市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第12章 競合ポートフォリオ

  • 主要企業プロファイル
    • Aark Pharmaceuticals
    • Active Biotech AB
    • Anant Pharmaceuticals Pvt. Ltd.
    • AstraZeneca PLC
    • Beijing Lunarsun Pharmaceutical Co., Ltd.
    • Bio-Techne Corporation
    • Brawn Laboratories Ltd.
    • Hetero Labs Limited
    • Hikma Pharmaceuticals PLC
    • JEIL PHARMACEUTICAL CO.,LTD.
    • Manus Aktteva Biopharma LLP
    • Medichem S.A.
    • Medzeel Lifescience
    • Nanjing First Pharmaceutical Co. Ltd,
    • Natco Pharma Limited
    • Pfizer Inc.
    • Shilpa Medicare Limited
    • Sichuan Xieli Pharmaceutical Co., Ltd.
    • Synthland Limited
    • Taj Pharma India Limited
    • TargetMol Chemicals Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Vivan Life Science
  • 主要製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SUNITINIB MALATE MARKET RESEARCH PROCESS
  • FIGURE 2. SUNITINIB MALATE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. SUNITINIB MALATE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SUNITINIB MALATE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. SUNITINIB MALATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SUNITINIB MALATE MARKET DYNAMICS
  • FIGURE 7. SUNITINIB MALATE MARKET SIZE, BY PURITY, 2023 VS 2030 (%)
  • FIGURE 8. SUNITINIB MALATE MARKET SIZE, BY PURITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. SUNITINIB MALATE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. SUNITINIB MALATE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 6. SUNITINIB MALATE MARKET SIZE, BY >97%, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SUNITINIB MALATE MARKET SIZE, BY >98%, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SUNITINIB MALATE MARKET SIZE, BY >99%, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 10. SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMORS (GISTS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA (RCC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY PURITY, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 100. SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. SUNITINIB MALATE MARKET LICENSE & PRICING
目次
Product Code: MRR-2A0283E256D3

[181 Pages Report] The Sunitinib Malate Market size was estimated at USD 123.27 million in 2023 and expected to reach USD 134.72 million in 2024, at a CAGR 9.79% to reach USD 237.13 million by 2030.

Global Sunitinib Malate Market

Sunitinib Malate Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Sunitinib Malate Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Sunitinib Malate Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Sunitinib Malate Market, highlighting leading vendors and their innovative profiles. These include Aark Pharmaceuticals, Active Biotech AB, Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Beijing Lunarsun Pharmaceutical Co., Ltd., Bio-Techne Corporation, Brawn Laboratories Ltd., Hetero Labs Limited, Hikma Pharmaceuticals PLC, JEIL PHARMACEUTICAL CO.,LTD., Manus Aktteva Biopharma LLP, Medichem S.A., Medzeel Lifescience, Nanjing First Pharmaceutical Co. Ltd,, Natco Pharma Limited, Pfizer Inc., Shilpa Medicare Limited, Sichuan Xieli Pharmaceutical Co., Ltd., Synthland Limited, Taj Pharma India Limited, TargetMol Chemicals Inc., Teva Pharmaceutical Industries Ltd., and Vivan Life Science.

Market Segmentation & Coverage

This research report categorizes the Sunitinib Malate Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Purity
    • >97%
    • >98%
    • >99%
  • Indication
    • Gastrointestinal Stromal Tumors (GISTs)
    • Pancreatic Neuroendocrine Tumors
    • Renal Cell Carcinoma (RCC)
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  • Market Penetration: It presents comprehensive information on the market provided by key players.
  • Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  • Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  • Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  • Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  • What is the market size and forecast of the Sunitinib Malate Market?
  • Which products, segments, applications, and areas should one consider investing in over the forecast period in the Sunitinib Malate Market?
  • What are the technology trends and regulatory frameworks in the Sunitinib Malate Market?
  • What is the market share of the leading vendors in the Sunitinib Malate Market?
  • Which modes and strategic moves are suitable for entering the Sunitinib Malate Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Sunitinib Malate Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in prevalence of pancreatic neuroendocrine tumors (pNET)
      • 5.1.1.2. Availability of limited drug options for treatment of advanced pNET
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of raw materials for manufacturing of sunitinib malate drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development by pharmaceutical companies to explore new indications and combinations for sunitinib malate
      • 5.1.3.2. Increasing awareness about the benefits of targeted therapies in cancer treatment among patients and healthcare providers
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse cardiovascular events reported during clinical trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Sunitinib Malate Market, by Purity

  • 6.1. Introduction
  • 6.2. >97%
  • 6.3. >98%
  • 6.4. >99%

7. Sunitinib Malate Market, by Indication

  • 7.1. Introduction
  • 7.2. Gastrointestinal Stromal Tumors (GISTs)
  • 7.3. Pancreatic Neuroendocrine Tumors
  • 7.4. Renal Cell Carcinoma (RCC)

8. Americas Sunitinib Malate Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Sunitinib Malate Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Sunitinib Malate Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Aark Pharmaceuticals
    • 12.1.2. Active Biotech AB
    • 12.1.3. Anant Pharmaceuticals Pvt. Ltd.
    • 12.1.4. AstraZeneca PLC
    • 12.1.5. Beijing Lunarsun Pharmaceutical Co., Ltd.
    • 12.1.6. Bio-Techne Corporation
    • 12.1.7. Brawn Laboratories Ltd.
    • 12.1.8. Hetero Labs Limited
    • 12.1.9. Hikma Pharmaceuticals PLC
    • 12.1.10. JEIL PHARMACEUTICAL CO.,LTD.
    • 12.1.11. Manus Aktteva Biopharma LLP
    • 12.1.12. Medichem S.A.
    • 12.1.13. Medzeel Lifescience
    • 12.1.14. Nanjing First Pharmaceutical Co. Ltd,
    • 12.1.15. Natco Pharma Limited
    • 12.1.16. Pfizer Inc.
    • 12.1.17. Shilpa Medicare Limited
    • 12.1.18. Sichuan Xieli Pharmaceutical Co., Ltd.
    • 12.1.19. Synthland Limited
    • 12.1.20. Taj Pharma India Limited
    • 12.1.21. TargetMol Chemicals Inc.
    • 12.1.22. Teva Pharmaceutical Industries Ltd.
    • 12.1.23. Vivan Life Science
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing